Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
November 23 2021 - 2:39PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
biopharmaceutical company developing and commercializing specialty
products for allergy, opioid overdose, respiratory and inflammatory
disease, today announced that it has received a letter from the
Listing Qualifications Department of The Nasdaq Stock Market LLC
(“NASDAQ”) notifying the company that based on the company’s filing
of its Quarterly Reports on Form 10-Q for the periods ended March
31, 2021, June 30, 2021 and September 30, 2021, the company has
regained compliance with NASDAQ Marketplace Rule 5250(c)(1), which
requires timely filing of periodic reports with the Securities and
Exchange Commission, and that the matter is now closed.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
company’s SYMJEPI (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. The company’s ZIMHI (naloxone)
Injection is approved for the treatment of opioid overdose. Tempol
is in development for the treatment of patients with COVID-19 and a
Phase 2/3 clinical trial is underway. For additional information
about Adamis Pharmaceuticals, please visit
www.adamispharmaceuticals.com and follow us on us on Twitter and
LinkedIn.
Contact:
Investor Relations atAdamis Pharmaceuticals Corporation (858)
997-2400 option 3IR@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024